secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2022-03-18T23:59:59+00:00
Accession:  0000950170-22-004161
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux reports FY2021 net loss $32.7M; cash $375M; IND filings for two TRACTr programs on track for 2022
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments $375.0M at Dec 31, 2021, vs $7.8M a year ago.
- Net loss $13.4M for Q4 2021 and $32.7M for FY2021; R&D expense $26.2M (FY2021).
- PSMA-TRACTr IND submission expected H1 2022; EGFR-TRACTr IND expected H2 2022.
- Nominated first TRACIr candidate, a PD-L1xCD28 costimulatory bispecific; IND planned for 2023.
- Appointed Byron Robinson, Ph.D., J.D., as Chief Strategy Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022004161/0000950170-22-004161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017022004161/janx-20220318.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-004161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer